Kazakh Sanlian (002900.SZ) announced semi-annual results, with a net loss of 44.1939 million yuan

According to Zhitong Finance App, Kazanlian (002900.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 429 million yuan, an increase of 3.79% over the same period last year; achieved a net loss of 44.1939 million yuan attributable to shareholders of listed companies; net loss of 53.1627 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss; basic earnings per share - 0.14 yuan.

The main reasons for the year-on-year increase in the company's operating performance during the reporting period were: the company actively developed the market and achieved positive results in improving quality and efficiency; the company's revenue increased by nearly 16 million yuan year on year, and the total operating cost decreased by nearly 10 million yuan year on year; the wholly-owned subsidiary “Lanxi Pharmaceutical” received government subsidies related to revenue, resulting in a year-on-year increase of more than 10 million yuan in other revenue; the company sold part of the inventory in the previous period to prepare for price reduction; at the same time, due to the rebound in market prices for some products, the company returned to prepare for price reduction in related inventory prices. The total impact of asset impairment losses in the current period due to the above resale and transfer matters was about $8.5 million, a decrease of $19.5 million compared to the same period last year.